Addex Therapeutics Ltd.
Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule allosteric modulators for neurological and neuropsychiatric disorders. Its work spans in-licensing, internal drug development, and equity interests in partnered and spin-out programs, with listings on the SIX Swiss Exchange and Nasdaq Capital Market.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaInternal small-molecule programs targeting neurological and respiratory indications.
Allosteric modulator assets advanced with external partners such as Indivior.
Ownership stakes in private companies advancing related neuroscience assets.
Discovery-stage neuroscience compounds and modulator platforms with optionality.
Asiakkaat
Addex does not sell commercial medicines to end patients; its main counterparties are pharmaceutical partners, clinical development collaborators, and future licensees. The company’s assets are designed for neurological, psychiatric, substance use, cough, and brain-injury indications, so value creation depends on out-licensing or partnering with larger drug developers. Equity interests in Neurosterix and Stalicla also align Addex with specialized biotech investors and strategic neuroscience collaborators.
Large and mid-sized drug companies that license Addex compounds for development and commercialization.
Partners like Indivior that co-fund or advance selected programs through preclinical and clinical stages.
Private neuroscience companies such as Neurosterix and Stalicla that expand the platform and option value.
Research groups and translational collaborators that use Addex compounds as tool assets or development candidates.
Strategia
Addex’s strategy is to build value in neuroscience by advancing a portfolio of differentiated allosteric modulators and preserving optionality through partnerships and spin-outs. The company focuses on indications where novel mechanism-of-action assets can be partnered to larger developers, while retaining selective internal programs such as chronic cough and brain-injury recovery.
Later-stage assets are the clearest path to partnering value and clinical validation.
Partnering can share development cost and broaden the reach of the platform.
Spin-outs and equity holdings can create non-dilutive value from adjacent programs.
Maantiede
Addex is headquartered in the United States in a corporate sense here, but its operational footprint is centered in Switzerland through its Swiss listing and European biopharmaceutical base. The company also has exposure to the United States through its NASDAQ-listed ADSs and U.S.-linked development partnerships, while its programs are intended for global pharmaceutical markets. Geography matters mainly through regulatory pathways, clinical trial execution, and cross-border partnering rather than manufacturing or commercial distribution.
Riskit
Addex depends on successful clinical development, partner execution, and regulatory progress across a small number of scientific programs, so setbacks in any one asset can materially affect value. As a clinical-stage biopharma company, it also faces the usual industry risks of trial failure, financing needs, IP protection, and uncertainty around when or whether partnered assets will advance.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
The portfolio is still clinical-stage and depends on positive efficacy and safety data.
Kohdistuu - Partner dependenceVaikutus: KorkeaTodennäköisyys: Korkea
Some programs are advanced or funded by partners, so timelines and priorities are partly outside Addex’s control.
Kohdistuu: Indivior collaboration and other partnered assets
- Capital and dilution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Drug development requires sustained funding before any commercialization cash flow exists.
Kohdistuu: Corporate overhead and internal program advancement
- Regulatory approval uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
CNS and novel-mechanism assets face stringent evidence requirements and unpredictable review outcomes.
Kohdistuu: All pipeline programs
Kirjanpito
Harkinnanvaraiset erätThe company records its share of net results from associates and spin-outs, which can move reported earnings without cash revenue.
Vaikutus: Neurosterix and other equity interests
Employee and director equity awards create non-cash expense that affects operating loss and equity.
Vaikutus: Operating expenses and reserves
Sales and repurchases of treasury shares affect equity balances and financing cash flow.
Vaikutus: Capital structure and cash flows
Swiss-franc reporting can create translation effects across cash and investments denominated in other currencies.
Vaikutus: Other comprehensive income and balance sheet
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
BioLineRx Ltd.
BLRX · Pharmaceutical Preparations
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Aditxt, Inc.
ADTX · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Agentix Corp.
AGTX · Biological Products, (No Diagnostic Substances)
Alector, Inc.
ALEC · Biological Products, (No Diagnostic Substances)
Päivitetty: 28.9.2026